Core Insights - Royal Philips, a leader in health technology, has announced the SEISMIC research consortium, which aims to transform neurosurgery through the integration of minimally invasive surgical techniques and advanced imaging technologies, supported by EUR 23.5 million in public funding and EUR 14.9 million in contributions from industry partners [1][6]. Group 1: Project Overview - The SEISMIC project will focus on improving patient care by shifting from open brain surgery to minimally invasive procedures, utilizing advanced imaging and precision navigation [2][4]. - The project will develop an integrated suite of technologies, including real-time surgical navigation combining ultrasound and live X-ray imaging, and minimally invasive biopsy and treatment techniques [5][6]. - The total budget for the five-year research program is EUR 38.4 million, which includes eight clinical studies to validate technical solutions for minimally invasive neurosurgery [6][7]. Group 2: Medical and Societal Impact - Neurological conditions, such as hemorrhagic stroke and brain tumors, are significant contributors to global health issues and socioeconomic costs, necessitating urgent minimally invasive treatment options [3][4]. - The SEISMIC project aims to reduce procedure times, minimize surgical trauma, and accelerate patient recovery, thereby improving clinical outcomes and expanding access to specialized neurosurgical care [7]. Group 3: Specific Conditions Addressed - The project will specifically target three critical neurological conditions: intracerebral hemorrhage, subdural hematoma, and brain tumors, focusing on enhancing surgical techniques and diagnostic methods [5][13]. - For intracerebral hemorrhage, the project will explore the use of real-time imaging to guide minimally invasive drainage devices [5][13]. - In addressing subdural hematoma, the team will investigate a combined procedure for drainage and embolization to prevent recurrence of bleeding [13]. - For brain tumors, SEISMIC will assess the use of cryoablation and focused ultrasound-enhanced liquid biopsy to reduce the need for open surgery [13].

Core Insights - The SEISMIC project, coordinated by Philips and funded by the EU's Innovative Health Initiative, aims to revolutionize neurosurgery by integrating advanced imaging and minimally invasive techniques to treat brain bleeding and tumors [2][3] Group 1: Project Overview - The SEISMIC project has a total budget of EUR 38.4 million, which includes EUR 23.5 million in public funding and EUR 14.9 million in in-kind contributions from industry partners [2] - The project will span five years and include eight clinical studies to validate technical solutions for minimally invasive neurosurgery [2] Group 2: Objectives and Innovations - The project seeks to shift from open brain surgery to minimally invasive procedures, enhancing patient care through advanced imaging and precision navigation [3][5] - SEISMIC will develop technologies such as real-time surgical navigation combining ultrasound and live X-ray imaging, simulation platforms for clinician training, and minimally invasive biopsy and treatment techniques [8] Group 3: Focus Areas - The project will address three critical neurological conditions: intracerebral hemorrhage, subdural hematoma, and brain tumors, which require surgical intervention for patient survival and quality of life [8][14] - Specific innovations include using real-time imaging for minimally invasive drainage of intracerebral hemorrhage, a combined procedure for subdural hematoma, and cryoablation for brain tumor treatment [14]

智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 2月9日上午，书记在北京国家信创园考察科技创新工作，接见北京脑科学与类脑研究所的所长罗敏敏等代表。 1月30日，中共中央政治局举行第二十四次集体学习，脑机接口作为"十五五"六大未来产业被重点学习。 我国高通量、可拉伸柔性电极解决行业痛点 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制 智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制出一款高通量、可拉伸柔性电极， 该技术解决了传统柔性电极在大脑动态运动时易移位、易脱出的核心问题，为植入式脑机接口长期稳定性提供了 底层解决方案，该成果于2月5日在《NatureElectronics》发表。 国产脑机全链布局，比肩甚至超越Neuralink 马斯克创办的Neuralink公司，首例人体植入术后数周，高达85%的柔性电极丝从该患者的脑组织中脱出。 智冉医疗已拥有电极植入手术机器人及微纳加工车间，可拉伸柔性电极达1024通道，实现从技术路径到工程参 数，比肩甚至超越Neuralink。 受益标的：创新医疗 ...

MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% ...

MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% ...

Core Viewpoint - CeriBell, Inc. is set to release its financial results for Q4 and the full year of 2025 on February 24, 2026, with a conference call scheduled to discuss these results [1]. Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3]. - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute-care settings [3]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3]. - The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S. [3]. - CeriBell is headquartered in Sunnyvale, California [3].

Philips Says The Turnaround Is Real And The Market Believes It - Moby THE GIST Philips delivered the kind of quarter that shifts the conversation from remediation to momentum. Orders rose, sales accelerated, margins expanded, and cash flow landed with confidence. The Respironics overhang still matters, but investors are increasingly treating Philips as a functioning medtech operator with improving fundamentals and a clearer runway. WHAT HAPPENED Philips reported 2025 group sales of €17.8 billion (about $ ...

MESA, AZ / ACCESS Newswire / February 10, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced it is executing a non-dilutive funding strategy supported by tangible, high-value assets held by its wholly owned subsidiary, Infinite Auctions, which currently maintains an estimated market value approaching $1 million in sports cards and elite game-worn memorabilia. This is exciting news with the pending release of the company's first AI based mobile application. ...

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. “This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to ...

Company Overview - Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.7 billion, focused on improving women's health through early disease detection and treatment [1] - The company develops and supplies diagnostic assays, medical imaging systems, and surgical solutions across its Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments [1] Stock Performance - Over the past 52 weeks, HOLX shares have increased by 16.2%, outperforming the S&P 500 Index, which gained 15.6% [2] - Year-to-date, HOLX stock has risen marginally, lagging behind the S&P 500's 1.7% return [2] - HOLX shares have outpaced the State Street Health Care Select Sector SPDR ETF (XLV), which returned 6.8% over the same period [3] Recent Financial Results - Following Q1 2026 results released on January 29, shares of Hologic fell marginally; adjusted EPS was $1.04 and revenue totaled $1.05 billion, both below expectations [5] - The decline in investor sentiment was attributed to weakness in Diagnostics revenue, margin compression due to $15.3 million in tariff-related costs, and the lack of forward guidance due to a pending acquisition by Blackstone and TPG [5] Future Earnings Expectations - For the fiscal year ending in September 2026, analysts expect HOLX's adjusted EPS to grow by 4.9% year-over-year to $4.47 [6] - The company's earnings surprise history is mixed, having topped consensus estimates in three of the last four quarters while missing on one occasion [6] - Among the 18 analysts covering the stock, the consensus rating is a "Hold" [6] Price Target - The mean price target for HOLX is $75.58, representing a marginal premium to its current price [8] - The highest price target of $79 suggests a potential upside of 5.3% [8]